Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... of building materials using light, developed by researchers at ... that are often considered the realm of science fiction, ... Although cloaked starships won,t be a reality for quite ... constructing materials with building blocks a few billionths of ... way that light flies through them, and works on ...
(Date:7/28/2014)... According to a new market research report published ... Joint) Market (By Technology - Stem Cell Therapy, ... Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products ... Growth, Trends and Forecast, 2013 - 2019" the ... valued at USD 2.6 billion in 2012 and ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... 28, 2014 Appistry, Inc. , ... bring the power of genomics to next-generation medicine, announced ... Pipeline Challenge . , Two Appistry staff will ... National Center for Genome Resources, and Mr. Neil Miller, ... of Kansas City. Rounding out the panel are Appistry’s ...
Breaking Biology Technology:Building 'invisible' materials with light 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... two new papers, Rice University researchers report using ultracentrifugation ... species. One team, led by Rice Professor Junichiro ... has made a small but significant step toward the ... on highly conductive quantum nanowire. The other, led ...
... , , ... Corp. (TSX:RVX) announced today that it will host a live teleconference and ... Eastern/ 11:00 am Mountain time . The purpose of the teleconference ... slide presentation followed by a question and answer session regarding the impact ...
... GUANGZHOU, China , May 10 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC ... of Western pharmaceuticals, traditional Chinese medicine,products, other nutraceuticals, medical devices, and ... 9:00 a.m. Eastern,Time on Thursday, May 13, 2010 to ... , , ...
Cached Biology Technology:Nano parfait a treat for scientists 2Nano parfait a treat for scientists 3Resverlogix Notice of Conference Call & Webcast for Year End Update 2China Medicine Announces Conference Call to Discuss First Quarter 2010 Results 2
(Date:7/27/2014)... patients, scientists have identified more than two dozen ... six that had not been previously reported. The ... partially funded by the National Institutes of Health ... laboratories. , "Unraveling the genetic underpinnings of Parkinson,s ... in this complex disease, and hopefully, may one ...
(Date:7/25/2014)... on the land now called California, and many of ... plants they used for food, fuel, tools, and ritual. ... habitat and natural resources. , Frank Lake, an ecologist ... lead a field trip to the Stone ... America,s 99th Annual Meeting, in Sacramento, Cal. this August. ...
(Date:7/25/2014)... wildfires have been raging this summer and some of the ... In this image collected by the Moderate Resolution Imaging ... a swath of smoke has descended over the Great Lakes ... is the fire image from July 23, 2014 (first image ... as it drifts off southeastward. In the image, it ...
Breaking Biology News(10 mins):NIH scientists find 6 new genetic risk factors for Parkinson's 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... a mystery with a stubby tail: an odd-looking mouse discovered through ... short, kinky tail and an extra set of ribs in its ... led by researchers at the University of California, San Francisco has ... so, they may have uncovered a new wrinkle in the genetic ...
... Stronger and tougher body armor to shield the chest, ... the Afghanistan and Iraq wars need to better protect their ... of a Johns Hopkins study in mice suggest. Such ... grenades and improvised explosive devices (IEDs) now accounts for more ...
... big effect on their life. Some people are outgoing ... can be detrimental to their health and wellbeing. Increasingly, ... , A new study led by Dr Kathryn Arnold, ... has added important experimental evidence showing that animal personalities ...
Cached Biology News:Mutant mouse reveals new wrinkle in genetic code, say UCSF scientists 2Mutant mouse reveals new wrinkle in genetic code, say UCSF scientists 3Shielding body protects brain from 'shell shocking' blast injuries 2Shielding body protects brain from 'shell shocking' blast injuries 3Animals have personalities, too 2
... Adhesion Molecule The L1CAM ... involved in three distinct conditions: 1) HSAS ... MASA (mental retardation, aphasia, shuffling gait, adductus ... Immunogen: Homogenous suspension of ...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... PP2A1, purified Formulation: 50mM ... 0.02% Brij-35, 0.2mM PMSF, 1mM ... glycerol. Properites: PP2A1 (Protein Phosphatase ... DEAE-Sephadex, ammonium sulfate precipitation, QSepharose,amino-hexyl ...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
Biology Products: